Notwithstanding promising clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant resistance from pharmacy benefit managers. The companies are https://haseebovjy909007.topbloghub.com/48625748/copyright-s-drug-faces-is-encountering-pbm-hurdles-a-review-of-reimbursement-disputes